BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21148080)

  • 1. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
    Teft WA; Mansell SE; Kim RB
    Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
    Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects.
    Keller DN; Medwid SJ; Ross CD; Wigle TJ; Kim RB
    Pharmacogenet Genomics; 2023 Jan; 33(1):10-18. PubMed ID: 36373739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of P-glycoprotein and multidrug resistance protein in transporting para-aminosalicylic acid and its N-acetylated metabolite in mice brain.
    Hong L; Xu C; O'Neal S; Bi HC; Huang M; Zheng W; Zeng S
    Acta Pharmacol Sin; 2014 Dec; 35(12):1577-85. PubMed ID: 25418377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
    Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
    Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
    Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
    Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
    J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.
    Kiyotani K; Mushiroda T; Nakamura Y; Zembutsu H
    Drug Metab Pharmacokinet; 2012; 27(1):122-31. PubMed ID: 22041137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
    Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat.
    Lacher SE; Gremaud JN; Skagen K; Steed E; Dalton R; Sugden KD; Cardozo-Pelaez F; Sherwin CM; Woodahl EL
    J Pharmacol Exp Ther; 2014 Feb; 348(2):336-45. PubMed ID: 24297779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
    Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells.
    Green LJ; Marder P; Slapak CA
    Biochem Pharmacol; 2001 Jun; 61(11):1393-9. PubMed ID: 11331075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.